Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Is yearly intravenous zoledronic acid comparable to weekly oral alendronate for postmenopausal osteoporosis?

Nature Clinical Practice Endocrinology & Metabolism volume 4, pages 20–21 (2008)Cite this article

boxed-textMcClung M et al. (2007) Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate. Bone 41: 122–128

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Cranney A et al. (2002) Meta-analyses of therapies for postmenopausal osteoporosis IX. Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 23: 570–578

    Article  CAS  Google Scholar 

  2. Michalskà D et al. (2006) The effect of raloxifene after discontinuation of long-term alendronate treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 91: 870–877

    Article  Google Scholar 

  3. Ettinger B et al. (2004) Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 19: 745–751

    Article  CAS  Google Scholar 

  4. Seeman E et al. (2007) Non-compliance: the Achilles' heel of anti-fracture efficacy. Osteoporos Int 18: 711–719

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Vicky Heath, Associate Editor, Nature Clinical Practice.

Author information

Author notes

  1. Department of Internal Medicine, Viale Pieraccini 6, 50139 Florence, Italy m.brandi@dmi.unifi.it

Authors and Affiliations

  1. ML Brandi is Full Professor of Endocrinology in the Department of Internal Medicine at the University of Florence, Florence, Italy.,

    Maria Luisa Brandi

Authors
  1. Maria Luisa Brandi
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Brandi, M. Is yearly intravenous zoledronic acid comparable to weekly oral alendronate for postmenopausal osteoporosis?. Nat Rev Endocrinol 4, 20–21 (2008). https://doi.org/10.1038/ncpendmet0673

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpendmet0673

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing